Home › civ
 

Keywords :   


Tag: civ

Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

2015-02-03 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively blocks orexin receptors. Language: English Contact: Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the united states medicine

 

Dr. Reddy's Announces the Launch of Eszopiclone Tablets C-IV

2014-04-16 17:03:52| Biotech - Topix.net

Dr. Reddy's Laboratories announced today that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTAA tablets C-IV in the US market on April 15, 2014, following the approval by the United States Food & Drug Administration .

Tags: launch announces tablets civ

 

Sites : [1]